Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.
From the official U.S. FDA label for ethambutol hydrochloride, the active ingredient registered with NAFDAC.
Ethambutol Hydrochloride Tablets, USP are indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. …
Ethambutol hydrochloride may produce decreases in visual acuity, including irreversible blindness, which appear to be due to optic neuritis. Optic neuropathy including optic neuritis or retrobulbar neuritis occurring in association with ethambutol therapy may be characterized by one or more of the following events: decreased visual acuity, scotoma, color blindness, and/or visual defect. These events have also been reported in the absence of a diagnosis of optic or retrobulbar neuritis. Patients should be advised to report promptly to their physician any change in visual acuity. …
Ethambutol hydrochloride is contraindicated in patients who are known to be hypersensitive to this drug. It is also contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be used. Ethambutol hydrochloride is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).
Ethambutol hydrochloride may produce decreases in visual acuity which appear to be due to optic neuritis. This effect may be related to dose and duration of treatment. This effect is generally reversible when administration of the drug is discontinued promptly. However, irreversible blindness has been reported. (See PRECAUTIONS and ADVERSE REACTIONS ). Liver toxicities including fatalities have been reported (See ADVERSE REACTIONS ). Baseline and periodic assessment of hepatic function should be performed.
Pregnancy Teratogenic Effects: Pregnancy Category C There are no adequate and well-controlled studies in pregnant women. There are reports of ophthalmic abnormalities occurring in infants born to women on antituberculous therapy that included ethambutol hydrochloride. Ethambutol hydrochloride should be used during pregnancy, only if the benefit justifies the potential risk to the fetus. …
Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.
Rifampicin 150 mg+ Isoniazid 75 mg + Pyrazinamide 400 mg + Ethambutol 275 mg Tablets USP contains Ethambutol Hydrochloride; Isoniazid; Pyrazinamide; Rifampicin (150 mg; 75 mg; 400 mg), as tablet, according to its NAFDAC registration record.
Yes. Rifampicin 150 mg+ Isoniazid 75 mg + Pyrazinamide 400 mg + Ethambutol 275 mg Tablets USP is listed on the NAFDAC register under registration number A4-100486, and its registration is active as of 6 November 2026.
No WHO falsified or substandard medical product alert currently matches Rifampicin 150 mg+ Isoniazid 75 mg + Pyrazinamide 400 mg + Ethambutol 275 mg Tablets USP in our automatically synced alert list.
Run a free authenticity scan with the NAFDAC number A4-100486, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.
Ethambutol Hydrochloride Tablets, USP are indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. … (Summarised from the official U.S. FDA label for ethambutol hydrochloride. Always follow your doctor or pharmacist.)
Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.